AVELI CONSULTING RYOGEN PATENT PORTFOLIO

Ryogen Patent Portfolio - Available for Acquisition

A 36-asset estate spanning oncology, cardio-metabolic disease, inflammation, virology and vesicle trafficking. Each block below summarizes the claim posture, gene focus and commercial relevance.

Strategic Acquisition Opportunity
Portfolio Summary

For detailed claim charts, transaction structures or portfolio diligence under NDA, please contact our business development lead.

[email protected]
+1 (251) 384-3687
Oncology Cardio-metabolic Inflammation Vesicle Traffic Regulatory / UTR
Patent Families
8 families shown.
MDM2 – p53 Pathway (Oncology)
oncology mdm2 p53
Patents in this family
  • US 8,956,819 – Identification of human MDM2 nucleotide sequences
  • US 8,771,956 – Modulation of human MDM2 activity
  • US 8,313,910 – MDM2 genomic sequences
  • US 7,964,357 – Early MDM2 sequence claims
  • US 7,754,424 – Combined CPM + MDM2 locus
Summary of claims
  • Defined MDM2 genomic fragments, including non-coding regions (UTRs, introns, splice markers).
  • Methods for identifying sequence variants in clinically relevant regions.
  • Probes, primers, kits and diagnostic tools built around these fragments.
  • Therapeutic claims covering modulation of MDM2 activity in a subject.
Disease & commercial relevance
  • Central regulator of the p53 tumor suppressor pathway.
  • Highly relevant to oncology diagnostics, companion diagnostics and targeted therapy development.
  • Strong alignment with comprehensive genomic profiling and whole-genome sequencing workflows.
Chromosome 11p15 Tumor-Suppressor Cluster
oncology 11p15
Patents in this family
  • US 8,399,642 – RPL26
  • US 8,399,641 – TSSC6
  • US 8,399,640 – SMS3
  • US 8,399,639 – HASH2 / ASCL2
  • US 8,765,928 – TSSC4 variants
  • US 8,765,927 – TSSC4 variants
  • US 8,722,865 – TSSC4 variants
  • US 8,399,638 – Isolated genomic polynucleotide fragments from the p15 region of chromosome 11
  • US 8,039,602 – 11p15 region (general)
Summary of claims
  • Isolates multiple tumor-suppressor and imprinting-related genes within the 11p15 region.
  • Covers genomic fragments across coding exons, introns, UTRs and marker gaps.
  • Includes broad umbrella claims with later gene-specific refinements.
Disease & commercial relevance
  • 11p15 is implicated in multiple cancers and in Beckwith–Wiedemann syndrome.
  • Links to CD81, a co-receptor relevant to Hepatitis C viral entry.
  • Useful for oncology, rare disease and imprinting-disorder diagnostics.
Chromosome 7 Cluster – GCK, POLD2, AEBP1, YKT6
metabolic chr7
Patents in this family
  • US 8,795,959 – Glucokinase (GCK) genomic fragments
  • US 8,822,145 – Identification of POLD2 sequences
  • US 8,313,900 – POLD2 genomic fragments
  • US 8,178,662 – AEBP1 genomic regions
  • US 8,323,884 – SNARE YKT6 genomic regions and uses
  • US 8,313,899 – SNARE YKT6 genomic regions
  • US 7,588,915 – Genomic polynucleotide fragments from chromosome 7 (omnibus)
Summary of claims
  • Defines genomic fragments and regulatory elements across a chr7 gene cluster (GCK, POLD2, AEBP1, YKT6).
  • Includes exonic, intronic and UTR segments suited for highly specific probes and primers.
  • Combines an early omnibus chr7 filing with later single-gene refinements.
Disease & commercial relevance
  • GCK is central to glucose sensing and monogenic diabetes.
  • POLD2 relates to DNA replication and repair signatures in oncology and hereditary disease.
  • AEBP1 and YKT6 link to inflammation, adiposity and vesicle trafficking.
RESISTIN + STXBP2 & Syntaxin Family
inflammation chr19
Patents in this family
  • US 8,372,588 – Isolated 3′-noncoding human RESISTIN fragments
  • US 8,283,118 – STXBP2 genomic fragments
  • US 8,012,687 – RESISTIN + STXBP2 dual-gene locus
  • US 7,470,522 – RESISTIN + STXBP2 dual-gene locus
  • US 8,057,998 – Syntaxin genomic fragments
Summary of claims
  • Covers regulatory and non-coding regions of RESISTIN, STXBP2 and Syntaxin.
  • Defines composite dual-gene loci with splice junctions and UTR coverage.
  • Provides tools for highly specific inflammatory and metabolic disease assays.
Disease & commercial relevance
  • RESISTIN is a key marker in obesity, insulin resistance and systemic inflammation.
  • STXBP2 / Syntaxin are involved in vesicle trafficking and immune function.
  • Multi-gene locus claims offer uncommon IP leverage in diagnostics.
PLA2G7 / Lp-PLA2 – Cardiometabolic Risk
cardio-metabolic
Patents in this family
  • US 7,468,266 – Lp-PLA2 genomic fragments
  • US 8,241,849 – Lp-PLA2 genomic fragments (continuation)
Summary of claims
  • Genomic fragments and non-coding regions of PLA2G7 (Lp-PLA2).
  • Probes, primers and kits for variant detection.
Disease & commercial relevance
  • Lp-PLA2 is widely used as a marker of cardiovascular inflammation and atherothrombotic risk.
  • Aligns with cardiometabolic risk panels and longitudinal monitoring programs.
Aminopeptidase P Isoforms – XPNPEP1 & XPNPEP2
protease
Patents in this family
  • US 7,273,718 – Soluble aminopeptidase P (XPNPEP1)
  • US 7,786,280 – Soluble aminopeptidase P (XPNPEP1)
  • US 8,258,273 – Soluble aminopeptidase P (XPNPEP1)
  • US 6,399,349 – Human aminopeptidase P gene (XPNPEP2, X-linked, membrane-bound)
Summary of claims
  • Defines the gene structure of two aminopeptidase P isoforms, including exons, introns and UTRs.
  • Supports design of probes, primers and constructs specific to each isoform.
Disease & commercial relevance
  • Relevant to cardiovascular, renal and inflammatory conditions.
  • Isoform- and chromosome-specific claims offer precise diagnostic stratification options.
Carboxypeptidases – CPM & CPD
oncology inflammation
Patents in this family
  • US 8,338,100 – Carboxypeptidase M (CPM)
  • US 8,058,052 – Carboxypeptidase M (CPM)
  • US 7,985,571 – Carboxypeptidase D (CPD)
  • US 7,754,424 – Combined CPM + MDM2 locus
Summary of claims
  • Genomic fragments and regulatory architecture for CPM and CPD.
  • Claims span coding and non-coding regions with utility in probe and kit design.
Disease & commercial relevance
  • Proteases implicated in cancer biology, inflammation and tissue remodeling.
  • The combined CPM + MDM2 locus patent offers cross-gene IP leverage.
RhoC Oncogene
oncology
Patents in this family
  • US 8,053,195 – RhoC genomic fragments
Summary of claims
  • Genomic fragments of the RhoC small GTPase oncogene.
  • Supports assays targeting metastatic and invasive cancer phenotypes.
Disease & commercial relevance
  • Relevant to aggressive solid tumors and metastasis biology.
  • Fits naturally into oncology gene panels focused on invasion and motility.
This page is a non-confidential summary intended for orientation only. Detailed claim language, prosecution history and enforcement analyses are available under NDA upon request.